USP Therapeutic Categories Model Guidelines
Therapeutic Category | Pharmacologic Class | Formulary Key Drug Types |
---|---|---|
Analgesics | Non-opioid Analgesics | |
Opioid Analgesics | Opioid Analgesics, Long-acting | |
Opioid Analgesics, Short-acting | ||
Anesthetics | Local Anesthetics | |
Antibacterials | Aminoglycosides | |
Beta-lactam, Cephalosporins | Cephalosporin Antibacterials, 1st Generation | |
Cephalosporin Antibacterials, 2nd Generation | ||
Cephalosporin Antibacterials, 3rd Generation | ||
Cephalosporin Antibacterials, 4th Generation | ||
Beta-lactam, Penicillins | Amino Derivative Penicillins | |
Extended Spectrum Penicillins | ||
Natural Penicillins | ||
Penicillinase-resistant Penicillins | ||
Beta-lactam, Other | ||
Macrolides | Erythromycins | |
Ketolides | ||
Macrolides (Non-erythromycins, Non-ketolides) | ||
Quinolones | ||
Sulfonamides | ||
Tetracyclines | ||
Antibacterials, Other | Antifolate Antibacterials | |
Glycopeptide Antibacterials | ||
Lincomycin Antibacterials | ||
Nitrofuran Antibacterials | ||
Oxazolidinone Antibacterials | ||
Miscellaneous Antibacterials | ||
Anticonvulsants | Calcium Channel Modifying Agents | |
Gamma-aminobutyric Acid (GABA) Augmenting Agents | ||
Glutamate Reducing Agents | ||
Sodium Channel Inhibitors | ||
Anticonvulsants, Other | ||
Antidementia Agents | Cholinesterase Inhibitors | |
Glutamate Pathway Modifiers | ||
Antidementia Agents, Other | ||
Antidepressants | Monoamine Oxidase Inhibitors | |
Serotonin/Norepinephrine Reuptake Inhibitors | ||
Tricyclics | ||
Antidepressants, Other | ||
Antidotes, Deterrents, and Toxicologic Agents | Antidotes | |
Deterrents | Alcohol Deterrents | |
Smoking Cessation Agents | ||
Toxicologic Agents | Opioid Antagonists | |
Antiemetics | 5-Hydroxytryptamine 3 (5-HT3) Antagonists | |
Neurokinin 1 (NK1) Receptor Antagonists | ||
Antiemetics, Other | ||
Antifungals | Allylamine Antifungals | |
Azole Antifungals | ||
Echinocandin Antifungals | ||
Polyene Antifungals | ||
Antifungals (Other) | ||
Antigout Agents | Renal Tubular Blocking Agents | |
Xanthine Oxidase Inhibitors | ||
Antigout Agents (Non-renal Tubular Blocking Agents and Non-xanthine Inhibitors) | ||
Anti-inflammatory Agents | Glucocorticoids | |
Nonsteroidal Anti-inflammatory Drugs | ||
Antimigraine Agents | Abortive | Ergot Alkaloids |
Triptans | ||
Prophylactic | Beta-adrenergic Blocking Agents | |
Antimigraine Agents, Prophylactic (Non–beta-adrenergic Blocking Agents) | ||
Antimyasthenic Agents | Parasympathomimetics | |
Antimycobacterials | Antituberculars | |
Antimycobacterials, Other | ||
Antineoplastics | Alkylating Agents | Ethylenimines/ Methylmelamines |
Nitrogen Mustards | ||
Nitrosoureas | ||
Alkylating Agents, Other | ||
Antiangiogenic Agents | ||
Antiestrogens/Modifiers | Estrogen-nitrosoureas | |
Selective Estrogen Receptor Modulators, 1st Generation | ||
Antimetabolites | Purine Analogs and Related Inhibitors | |
Antimetabolites, Other | ||
Aromatase Inhibitors, 3rd Generation | ||
Molecular Target Inhibitors | Epidermal Growth Factor Receptor Kinase Inhibitors | |
Multitargeted Kinase Inhibitors, Bcr-Abl/c-kit Receptor Tyrosine Kinases | ||
Multitargeted Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor Tyrosine Kinases | ||
Monoclonal Antibodies | Anti-CD20 Antibodies | |
Retinoids | ||
Antineoplastics, Other | ||
Antiparasitics | Anthelmintics | |
Antiprotozoals | Antimalarials | |
Antiprotozoals (Non-antimalarials) | ||
Pediculicides/ Scabicides | ||
Antiparkinson Agents | Anticholinergics | |
Catechol O-methyltransferase (COMT) Inhibitors | ||
Dopamine Agonists, Ergot | ||
Dopamine Agonists, Nonergot | ||
Dopamine Precursors | ||
Monoamine Oxidase B (MAO-B) Inhibitors | ||
Antiparkinson Agents, Other | ||
Antipsychotics | Atypicals | |
Conventional | ||
Antispasticity Agents | ||
Antivirals | Anti-cytomegalovirus (CMV) Agents | |
Antihepatitis Agents | ||
Antiherpetic Agents | ||
Anti-human Immunodeficiency Virus (HIV) Agents, Fusion Inhibitors | ||
Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors | ||
Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | ||
Anti-HIV Agents, Protease Inhibitors | ||
Anti-influenza Agents | ||
Anxiolytics | Antidepressants | |
Anxiolytics, Other | ||
Bipolar Agents | ||
Blood Glucose Regulators | Antidiabetic Agents | Alpha Glucosidase Inhibitors |
Amylinomimetics | ||
Biguanides | ||
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | ||
Incretin Mimetics | ||
Meglitinides | ||
Sulfonylureas | ||
Thiazolidinediones | ||
Glycemic Agents | ||
Insulins | Insulin, Rapid-acting | |
Insulin, Short-acting | ||
Insulin, Intermediate-acting | ||
Insulin, Long-acting | ||
Insulin Mixtures, Short-acting and Intermediate-acting | ||
Insulin Mixtures, Analogs | ||
Blood Products/Modifiers/Volume Expanders | Anticoagulants | Anticoagulants, Oral |
Factor Xa Inhibitors, Indirect | ||
Low Molecular Weight Heparins | ||
Blood Formation Products | Colony Stimulating Factors | |
Erythropoietins | ||
Coagulants | Protease Inhibitors | |
Platelet Aggregation Inhibitors | Adenosine Diphosphate P2Y12 Inhibitors | |
Cyclic Adenosine Monophosphate Reuptake Inhibitors | ||
Phosphodiesterase III/Adenosine Uptake Inhibitors | ||
Cardiovascular Agents | Alpha-adrenergic Agonists | |
Alpha-adrenergic Blocking Agents | ||
Antiarrhythmics | Antiarrhythmics - Classes IA, B, and C | |
Antiarrhythmics - Class Ia/II/III/IV | ||
Antiarrhythmics - Class II | ||
Antiarrhythmics - Class II/III | ||
Antiarrhythmics - Class III | ||
Antiarrhythmics - Class IV | ||
Beta-adrenergic Blocking Agents | Alpha-beta–adrenergic Blocking Agents | |
Cardioselective Beta-adrenergic Blocking Agents | ||
Nonselective Beta-adrenergic Blocking Agents | ||
Calcium Channel Blocking Agents | Calcium Channel Blocking Agents (Non-dihydropyridines) | |
Dihydropyridines | ||
Diuretics | Carbonic Anhydrase Inhibitors | |
Loop Diuretics | ||
Potassium-sparing Diuretics | ||
Thiazide Diuretics | ||
Dyslipidemics | Bile Acid Sequestrants | |
Cholesterol Absorption Inhibitors | ||
Fibrates | ||
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) Reductase Inhibitors | ||
Nicotinic Acid | ||
Omega-3 Fatty Acids | ||
Renin-angiotensin-aldosterone System Inhibitors | Aldosterone Receptor Antagonists | |
Angiotensin-converting Enzyme (ACE) Inhibitors | ||
Angiotensin II Receptor Antagonists | ||
Vasodilators | Vasodilators, Direct-acting Arterial | |
Vasodilators, Direct-acting Arterial/Venous | ||
Vasodilators, Endothelin Receptor Antagonists | ||
Cardiovascular Agents, Other | ||
Central Nervous System Agents | Amphetamines, ADHD | |
Non-amphetamines, ADHD | ||
Non-amphetamines, Other | ||
Dental and Oral Agents | ||
Dermatological Agents | Dermatological Acne Agents | |
Dermatological Anti-inflammatory Agents | ||
Dermatological Antipruritic Agents | ||
Dermatological Calcineurin Inhibitors | ||
Dermatological Caustic Agents | ||
Dermatological Emollients | ||
Dermatological Genital Wart Agents | ||
Dermatological Mitotic Inhibitors | ||
Dermatological Non-melanoma Skin Cancer Agents | ||
Dermatological Photochemotherapy Agents | ||
Dermatological Psoriasis Agents | ||
Dermatological Wound Care Agents | ||
Enzyme Replacements/Modifiers | Anti-cystine Agents | |
Fabry Disease Treatment | ||
Gaucher's Disease Treatment | ||
Glucosylceramide Synthase Inhibitors | ||
Hereditary Tyrosinemia Type 1 (HT-1) Treatment | ||
Homocystinuria Treatment | ||
Hunter Syndrome Treatment | ||
Mucopolysaccharidosis Disease Treatment | ||
Pancrelipase Replacement | ||
Severe Combined Immunodeficiency Disease (SCID) Treatment | ||
Sucrase Enzyme Replacement | ||
Urea Cycle Disorder Treatment | ||
Gastrointestinal Agents | Antispasmodics, Gastrointestinal | |
Histamine2 (H2) Blocking Agents | ||
Irritable Bowel Syndrome Agents | ||
Protectants | ||
Proton Pump Inhibitors | ||
Gastrointestinal Agents, Other | ||
Genitourinary Agents | Antispasmodics, Urinary | |
Benign Prostatic Hypertrophy Agents | Alpha 1-adrenergic Blocking Agents | |
5 Alpha-reductase Inhibitors | ||
Phosphate Binders | ||
Genitourinary Agents, Other | ||
Hormonal Agents, Stimulant/ Replacement/ Modifying (Adrenal) | Glucocorticoids/ Mineralocorticoids | Glucocorticoids-Systemic |
Glucocorticoids-Topical-Low Potency | ||
Glucocorticoids-Topical-Medium Potency | ||
Glucocorticoids-Topical-High Potency | ||
Glucocorticoids-Topical-Very High Potency | ||
Mineralocorticoids | ||
Hormonal Agents, Stimulant/ Replacement/ Modifying (Pituitary) | Gonadotropins | |
Growth Hormone Analogs | ||
Insulin-like Growth Factor Analogs | ||
Vasopressin Analogs | ||
Hormonal Agents, Stimulant/ Replacement/ Modifying (Prostaglandins) | ||
Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers) | Anabolic Steroids | |
Androgens | ||
Estrogens | ||
Progestins | ||
Selective Estrogen Receptor Modifying Agents | ||
Hormonal Agents, Stimulant/ Replacement/ Modifying (Thyroid) | ||
Hormonal Agents, Suppressant (Adrenal) | ||
Hormonal Agents, Suppressant (Parathyroid) | Calcimimetics | |
Hormonal Agents, Suppressant (Pituitary) | Dopamine Agonists | |
Gonadotropin-releasing Hormone Analogs | ||
Growth Hormone Antagonists | ||
Somatostatin Analogs | ||
Hormonal Agents, Suppressant (Sex Hormones/ Modifiers) | Antiandrogens | |
Hormonal Agents, Suppressant (Thyroid) | Antithyroid Agents | |
Immunological Agents | Immune Stimulants | Vaccines to Prevent Anthrax |
Vaccines to Prevent Diphtheria | ||
Vaccines to Prevent Haemophilus Type B | ||
Vaccines to Prevent Hepatitis A | ||
Vaccines to Prevent Hepatitis B | ||
Vaccines to Prevent Japanese Encephalitis | ||
Vaccines to Prevent Measles | ||
Vaccines to Prevent Meningococcal Disease | ||
Vaccines to Prevent Mumps | ||
Vaccines to Prevent Papillomavirus Disease | ||
Vaccines to Prevent Pertussis | ||
Vaccines to Prevent Poliovirus | ||
Vaccines to Prevent Rabies | ||
Vaccines to Prevent Rotavirus Disease | ||
Vaccines to Prevent Rubella | ||
Vaccines to Prevent Tetanus | ||
Vaccines to Prevent Typhoid | ||
Vaccines to Prevent Varicella | ||
Vaccines to Prevent Yellow Fever | ||
Vaccines to Prevent Zoster | ||
Immune Suppressants | Immune Suppressants (Non-TNF Inhibitors) | |
Tumor Necrosis Factor (TNF) Inhibitors | ||
Immunizing Agents, Passive | Immunoglobulins | |
Immunomodulators | Interferons, Alfa | |
Interferons, Beta | ||
Interferons, Gamma | ||
Immunomodulators, Other | ||
Inflammatory Bowel Disease Agents | Glucocorticoids | |
Salicylates | ||
Sulfonamides | ||
Metabolic Bone Disease Agents | Bisphosphonates, Oral | |
Bisphosphonates, Parenteral | ||
Calcium Regulating Hormones | ||
Parathyroid Hormone Analogs | ||
Vitamin D–related Agents/Metabolic Bone Disease Agents | ||
Ophthalmic Agents | Ophthalmic Anti-allergy Agents | |
Ophthalmic Antiglaucoma Agents | Alpha-adrenergic Agonists, Ophthalmic | |
Beta-adrenergic Blocking Agents, Ophthalmic | ||
Carbonic Anhydrase Inhibitors, Ophthalmic | ||
Cholinergic Agonists, Ophthalmic | ||
Ophthalmic Anti-inflammatories | Glucocorticoids, Ophthalmic | |
Nonsteroidal Anti-inflammatory Drugs, Ophthalmic | ||
Ophthalmic Prostaglandin and Prostamide Analogs | ||
Ophthalmic Agents, Other | ||
Otic Agents | Otic Anti-inflammatories | |
Respiratory Tract Agents | Antihistamines | Histamine1 (H1) Blocking Agents, Mildly/Non-sedating |
H1 Blocking Agents, Sedating | ||
Anti-inflammatories, Inhaled Corticosteroids | ||
Antileukotrienes | Receptor Antagonists | |
Synthesis Inhibitors | ||
Bronchodilators, Anticholinergic | ||
Bronchodilators, Phosphodiesterase Inhibitors (Xanthines) | ||
Bronchodilators, Sympathomimetic | ||
Mast Cell Stabilizers | ||
Pulmonary Antihypertensives | ||
Respiratory Tract Agents, Other | ||
Sedatives/Hypnotics | ||
Skeletal Muscle Relaxants | ||
Therapeutic Nutrients/Minerals/ Electrolytes | Electrolytes/Minerals | |
Vitamins | Prenatal Vitamins |